Table 3

Relationship between expression of MLH1 and clinicopathological parametersa for the patients with neoadjuvant chemotherapy and surgery (RO)

MLH1 expressionTotal n = 97 (%)
High n = 61 (%)Low n = 36 (%)
Age58.9 ± 8.359.0 ± 6.859.0 ± 7.8
Gender
 Male49 (80.3)33 (91.7)82 (84.5)
 Female12 (19.7)3 (8.3)15 (15.5)
Locationb
 Ut12 (19.7)5 (13.9)17 (17.5)
 Mt28 (45.9)18 (50.0)46 (47.4)
 Lt21 (34.4)13 (36.1)34 (35.1)
Histological type
 G117 (27.9)4 (11.1)21 (21.6)
 G230 (49.1)22 (61.1)52 (54.6)
 G314 (23.0)10 (27.8)24 (24.8)
Depth of invasion
 T321 (34.4)13 (36.1)34 (35.1)
 T440 (65.6)23 (63.9)63 (64.9)
LN metastasis
 NO18 (29.5)8 (22.2)26 (26.8)
N1 and/or M1 lymph43 (70.5)28 (77.8)71 (73.2)
  • a Based on Tumor-Node-Metastasis classification diagnosed by computed tomography scan and esophagograph before chemotherapy.

  • b Ut, upper thoracic esophagus; Mt, middle thoracic esophagus; Lt, lower thoracic esophagus.